Axsome Therapeutics (AXSM) Current Leases (2020 - 2026)

Axsome Therapeutics (AXSM) has 7 years of Current Leases data on file, last reported at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 603.3% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 603.3% YoY), and the FY2025 full-year result was $2.5 million, up 38.69% from the prior year.
• Current Leases improved to $3.2 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $3.2 million in Q1 2026 to a low of $108000.0 in Q1 2023.
• A 5-year average of $1.1 million and a median of $709120.0 in 2022 frame the typical range for Current Leases.
• Across the five-year window, Current Leases plunged 88.83% in 2023 and surged 603.3% in 2026, its largest moves.
• Tracing AXSM's Current Leases over 5 years: stood at $425000.0 in 2022, then soared by 198.12% to $1.3 million in 2023, then surged by 44.83% to $1.8 million in 2024, then surged by 38.69% to $2.5 million in 2025, then gained by 25.46% to $3.2 million in 2026.
• Business Quant data shows AXSM's Current Leases at $3.2 million in Q1 2026, $2.5 million in Q4 2025, and $2.5 million in Q3 2025.